Patent AnalyticsExaminers
Rankings

Company or institution

AGENEBIO, INC.

23 applicationsfiled 2013 to 2023

Allowance rate
80%
+5 pts vs the USPTO range 58% to 92%
Rejections before allowance
2.2
+0.6 vs the USPTO
Months to first action
13.5 mo
−5.1 vs the USPTO
Needed an RCE
43%
+16 pts vs the USPTO

Timeline

Applications by filing year: drag across the years to study a period

Allowed in green, abandoned in red, pending in grey. The figures above and the charts that can be recomputed by filing year follow the span you pick.

Compared with the office

Against every applicant before the USPTO

Unlock the comparison with the officeFree with an account. No card needed.

Create a free account

Trend

Allowance by filing year

Unlock the trendIncluded in Pro, from $29 a month. Cancel any time.

See plans Sign in

Domains

Where the applications fall

CPC subclasses

A61K Medical preparations10 apps
C07D Heterocyclic compounds7 apps
A61P Therapeutic activity of compounds6 apps

Art units

162410 apps
16154 apps
16284 apps
16992 apps
16272 apps
16231 apps

Who represents them

Law firms and agents on their applications

Bars show the share of decided applications that were allowed.

Unlock the firms on their applicationsIncluded in Pro, from $29 a month. Cancel any time.

See plans Sign in

Rejection fingerprint

What gets rejected, by statute

Share of parsed office actions raising each ground; blue is the USPTO.

Unlock the rejection fingerprintIncluded in Pro, from $29 a month. Cancel any time.

See plans Sign in

What works

Allowance by strategy used

Unlock what works for this filerIncluded in Pro, from $29 a month. Cancel any time.

See plans Sign in

Interviews

Does an interview help?

Unlock the interview figuresFree with an account. No card needed.

Create a free account

Applications

Every application in the record

ApplicationTitleFiledStatusRejectionsRCEsTo 1st action
18235753BENZAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT2023-08-18Allowed1027.7 mo
18015439COMBINATIONS OF GABAA ALPHA 5 AGONISTS AND SV2A INHIBITORS AND METHODS OF USING IN …2023-01-10Pending1030.7 mo
18015445POLYMORPHS OF A GABAA ALPHA5 AGONIST AND METHODS OF USING IN THE TREATMENT OF COGNI…2023-01-10Allowed1033.1 mo
15588575Method and apparatus for adaptive signal processing2012-01-10Allowed1012.0 mo
15312406Composition and method for controlled release2015-02-11Abandoned4123.0 mo
15718323Distributed ledger transaction verification2018-03-12Allowed3020.0 mo
15502862Thermal management of battery assemblies2021-04-13Pending2117.0 mo
15946104Machine learning model for anomaly detection2012-05-14Allowed1014.0 mo
15876844Wireless power transfer coil arrangement2015-06-15Abandoned4125.0 mo
15727203Catalyst for selective hydrogenation2018-07-16Allowed3022.0 mo
Unlock all 23 applications, each with its full timelineIncluded in Pro, from $29 a month. Cancel any time.

See plans Sign in